Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11739-019-02149-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society.
Kardiol Pol
June 2023
Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Heart failure (HF) remains one of the most common causes of hospitalization and mortality among Polish patients. The position of the Section of Cardiovascular Pharmacotherapy presents the currently applicable options for pharmacological treatment of HF based on the latest European and American guidelines from 2021-2022 in relation to Polish healthcare conditions. Treatment of HF varies depending on its clinical presentation (acute/chronic) or left ventricular ejection fraction.
View Article and Find Full Text PDFHypertension and Type 2 Diabetes-The Novel Treatment Possibilities.
Int J Mol Sci
June 2022
Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland.
Elevated blood pressure and hyperglycaemia frequently coexist and are both components of metabolic syndrome. Enhanced cardiovascular risk is strongly associated with diabetes and the occurrence of hypertension. Both hypertension and type 2 diabetes, if treated inappropriately, lead to serious complications, increasing the mortality of patients and generating much higher costs of health systems.
View Article and Find Full Text PDFNew therapeutic options for patients with heart failure with reduced ejection fraction and acute decompensated heart failure.
Adv Med Sci
March 2022
Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland.
Background: Patients with acute decompensated heart failure (ADHF) are at severe risk of death and rehospitalization. Several clinical studies have been designed to evaluate the efficacy and safety of new molecules administered before discharge or shortly after ADHF. The aim of this article is to summarize current knowledge on recently published findings on treatment of patients with heart failure with reduced ejection fraction (HFrEF) and ADHF.
View Article and Find Full Text PDFRenal protection in chronic heart failure: focus on sacubitril/valsartan.
Eur Heart J Cardiovasc Pharmacother
September 2021
Department of Advanced Biomedical Sciences, Federico II University of Naples, Via Pansini, 5, 80131 Naples, Italy.
Chronic kidney disease (CKD) is highly prevalent in patients with chronic heart failure (CHF) and increases the risk of overall and cardiovascular (CV) mortality. Despite evidence supporting the effectiveness of angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers, and mineralocorticoid receptor antagonists in decreasing mortality in patients with CHF, CKD hampers the optimization of standard pharmacologic therapy for heart failure. Therefore, other treatment options are needed to optimize treatment outcomes in CHF patients with CKD.
View Article and Find Full Text PDF[SGLT2 inhibitors: A new era for our patients].
Nephrol Ther
June 2021
Service de néphrologie-HTA, dialyses et transplantation rénale, hôpital Bretonneau, CHU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex, France. Electronic address:
Article Synopsis
- Since 2015, 10 major clinical trials involving over 88,000 patients have evaluated the cardiovascular and renal safety benefits of SGLT2 inhibitors, with key studies like EMPAREG Outcome showing unexpected significant protection for these organs.
- The drugs—dapagliflozin, canagliflozin, empagliflozin, and sotagliflozin—demonstrated substantial renal protection in patients on other therapies, along with a notable reduction in heart failure hospitalizations, particularly for those with reduced ejection fraction.
- While the benefits of SGLT2 inhibitors are well-documented, potential side effects, including serious conditions, must be considered as these drugs now set a new standard of care,
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!